公开(公告)号：KR1020090036030A

公开(公告)日：2009-04-13

申请号：KR1020070101118

申请日：2007-10-08

Applicant: 삼성전자주식회사 ,  재단법인서울대학교산학협력재단

Inventor： 이동현 ,  김영환 ,  최성태 ,  최정환 ,  황철규 ,  권영우 ,  최우열

IPC: H01P3/08

CPC classification number: H01P11/001 ,  H01P3/003 ,  H01P3/081 ,  Y10T29/49016

Abstract: A multi-metal waveguide and manufacturing method thereof is provided to minimize loss by increasing a current distribution area through insertion of an insulating layer between metal layers. A plurality of metal layers is laminated on a substrate while a power transmission line which is composed of a plurality of metal including a signal line(200). The signal line comprises a first signal part(210) and a second signal part(220). The first signal part is formed in at least one of metal layers and is formed with separated with a ground line. The second signal part has the width wider than that of the first signal part while being separated with the ground line by a different height. The transmission line of the multi-metal includes a metal connection unit(300).

Abstract translation: 提供多金属波导及其制造方法，以通过在金属层之间插入绝缘层来增加电流分布面积来最小化损耗。 多个金属层层叠在基板上，而由包括信号线（200）的多个金属构成的输电线路。 信号线包括第一信号部分（210）和第二信号部分（220）。 第一信号部分形成在金属层中的至少一个中，并且被形成为用接地线分开。 第二信号部分的宽度比第一信号部分的宽度宽，同时用接地线分开不同的高度。 多金属的传输线包括金属连接单元（300）。

公开(公告)号：KR101425796B1

公开(公告)日：2014-08-04

申请号：KR1020070101118

申请日：2007-10-08

Applicant: 삼성전자주식회사 ,  재단법인서울대학교산학협력재단

Inventor： 이동현 ,  김영환 ,  최성태 ,  최정환 ,  황철규 ,  권영우 ,  최우열

IPC: H01P3/08

CPC classification number: H01P11/001 ,  H01P3/003 ,  H01P3/081 ,  Y10T29/49016

Abstract: 본 발명은 다층 금속 구조체의 전송선로 및 이의 형성 방법에 관한 것으로, 기판상에 다수의 금속층을 적층하되, 각 금속층간에 절연층이 삽입되는 다층 금속 구조체의 전송선로에 있어서, 신호선과 접지선 사이의 전류 분포를 넓은 면적에 분산하여 도전체 손실을 최소화할 수 있도록 한 것이다.
다층 금속 구조, 전송선로, 신호선, 접지선, 손실

公开(公告)号：KR100772078B1

公开(公告)日：2007-10-31

申请号：KR1020060109667

申请日：2006-11-07

Applicant: 한국기초과학지원연구원 ,  재단법인서울대학교산학협력재단

Inventor： 노정래 ,  김영환 ,  김은희 ,  이철현

IPC: C07H1/06

CPC classification number: C07H15/10 ,  C07H1/08

Abstract: Novel monogalactosyldiacylglycerol compounds isolated from Sargassum Thunbergii are provided which shows anti-fungal activity on Candida albican and contains both alpha-linoleic acid and eicosapentaenoic acid(EPA). A [(2S)-1-O-(5Z,8Z,11Z,14Z,17Z -eicosapentaenoyl)-2-O-(9Z,12Z,15Z-octadecatrienoyl)-3-O-beta-Dgalactopyranosyl-sn-glycerol] is represented by the formula(1). A (2S)-1-O-(9Z,12Z,15Z-octadecatrienoyl)-2-O-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-3-O-beta-D-galactopyranosyl-sn-glycerol is represented by the formula(2). A method for preparing the monogalactosyldiacylglycerol compound comprises the steps of: (a) after mixing cut Sargassum Thunbergii with methanol in a weight ratio of 1:1-1:3 and leaving it for 48-72 hours, filtering it; (b) concentrating the methanol filtrate under reduced pressure and adding a mixture solution of butanol and water in a weight ratio of 1:1 thereto; (c) concentrating solvent of the butanol layer under reduced pressure and adding a mixture solution consisting of methanol and water in a weight ratio of 15:85 and normal hexane thereto; and (d) concentrating solvent of the methanol layer under reduced pressure and isolating the desired product through a reverse silica flash chromatography.

Abstract translation: 提供了从马齿苋（Thargarum Thunbergii）分离的新型单糖半乳糖二甘油化合物，其显示白念珠菌（Candida albican）的抗真菌活性，并含有α-亚油酸和二十碳五烯酸（EPA）。 A [（2S）-1-O-（5Z，8Z，11Z，14Z，17Z-二十碳烯酰基）-2-O-（9Z，12Z，15Z-十八碳三烯酰基）-3-O-β-D-吡喃半乳糖基-sn-甘油] 由式（1）表示。 代表了（2S）-1-O-（9Z，12Z，15Z-十八碳三烯酰基）-2-O-（6Z，9Z，12Z，15Z-十八碳四烯酰基）-3-O-β-D-吡喃半乳糖基-sn-甘油 通过式（2）。 制备单半乳糖基二酰基甘油化合物的方法包括以下步骤：（a）将切碎的马鞭草皂甙与甲醇以1：1-1：3的重量比混合48-72小时后，过滤; （b）减压浓缩甲醇滤液，加入重量比为1:1的丁醇和水的混合溶液; （c）在减压下浓缩丁醇层的溶剂，并加入由甲醇和水组成的重量比为15:85的混合溶液和正己烷; 和（d）减压浓缩甲醇层的溶剂，并通过反向硅胶快速色谱法分离所需产物。

公开(公告)号：KR1020090028880A

公开(公告)日：2009-03-20

申请号：KR1020070093995

申请日：2007-09-17

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김인규 ,  신동명 ,  조성엽 ,  정의만 ,  장기용 ,  박상철 ,  이동섭 ,  오근희 ,  김영환

IPC: A61K31/198 ,  A61K31/13 ,  A61P11/00 ,  A61P1/16

CPC classification number: A61K31/198

Abstract: A pharmaceutical composition including a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC) is provided to prevent or cure fibrosis and to specifically show the molecular mechanism about the fibrosis. A pharmaceutical composition for preventing and treating fibrosis comprises (a) pharmaceutically effective dose of a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC); and (b)a pharmaceutically allowable carrier. A screening method of a material for preventing and treating fibrosis comprises the steps of: (i) contacting a testing material with a transglutaminase(TGase 2) protein; and (ii) measuring the activity of the TGase 2. The transglutaminase(TGase 2) inhibitor is the cystamine or the cysteamine.

Abstract translation: 提供包含转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）的药物组合物，以预防或治愈纤维化，并具体显示纤维化的分子机制。 用于预防和治疗纤维化的药物组合物包括（a）药学有效剂量的转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）; 和（b）药学上可允许的载体。 用于预防和治疗纤维化的材料的筛选方法包括以下步骤：（i）使测试材料与转谷氨酰胺酶（TGase 2）蛋白质接触; 和（ii）测量TGase 2的活性。转谷氨酰胺酶（TGase 2）抑制剂是胱胺胺或半胱胺。